1. Home
  2. SOS vs TPST Comparison

SOS vs TPST Comparison

Compare SOS & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOS Limited

SOS

SOS Limited

HOLD

Current Price

$0.91

Market Cap

18.2M

Sector

Finance

ML Signal

HOLD

Logo Tempest Therapeutics Inc.

TPST

Tempest Therapeutics Inc.

HOLD

Current Price

$0.86

Market Cap

15.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOS
TPST
Founded
2004
2011
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.2M
15.6M
IPO Year
2005
2012

Fundamental Metrics

Financial Performance
Metric
SOS
TPST
Price
$0.91
$0.86
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$11.00
AVG Volume (30 Days)
17.7K
126.1K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$295,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.84
52 Week High
$2.89
$12.22

Technical Indicators

Market Signals
Indicator
SOS
TPST
Relative Strength Index (RSI) 37.96 30.47
Support Level $0.91 N/A
Resistance Level $1.09 $1.09
Average True Range (ATR) 0.07 0.07
MACD -0.01 0.01
Stochastic Oscillator 10.53 11.97

Price Performance

Historical Comparison
SOS
TPST

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing and other Hosting services. The company has single reporting segment: Commodity trading and generates key revenue is generated from Commodity trading.

About TPST Tempest Therapeutics Inc.

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Share on Social Networks: